Urodynamix Enters into Definitive Agreement for Sale of NIRS Business to HEGLN (Dalian)

Urodynamix Technologies Ltd. (TSX VENTURE:URO) ("Urodynamix" or the "Company")
announces today that it has signed a definitive agreement with HEGLN (Dalian)
for the sale of the majority of its assets for CAD$2,100,000. HEGLN is a leading
Chinese biotechnology company. The acquisition of the Urodynamix assets will
allow HEGLN to expand its product offering in its domestic and worldwide
markets.


"As described in the press release dated December 9, 2009, the Company has been
investigating strategic initiatives to maximize shareholder value in light of
the previously announced changes in US reimbursement for its uroNIRS products,"
said Barry Allen, President and CEO of Urodynamix. "This transaction will also
insure that this valuable technology will continue to be available worldwide."


"We are excited by the opportunity to acquire such valuable technology. We will
continue to work with our network of researchers, contractors and distributors
to further develop and market the uroNIRS products worldwide," said Zhe Qin,
President of HEGLN.


This agreement is subject to the approval of the University of British Columbia,
the National Research Council of Canada, and the Company's shareholders. Further
information and details will be available in the Company's information circular,
which will be mailed to shareholders shortly. Shareholder approval will be
sought at the Company's Annual General and Special Meeting to be held prior to
August 30th, 2010.


Following closing, the transaction, Urodynamix management will evaluate
alternatives to maximize shareholder value and will provide updates as they
become available.


About Urodynamix

Urodynamix is a Canadian medical device company developing and commercializing
non-invasive medical technology based on proprietary applications of
near-infrared spectroscopy (NIRS). The Company is currently focused on products
that aid in the diagnosis and treatment of urinary incontinence, lower urinary
tract symptoms, erectile dysfunction, prostate cancer, benign prostatic
hyperplasia, and traumatic increased in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


About HEGLN (Dalian)

HEGLN (Dalian) Pharmaceutical Co., Ltd. is located in Dalian, China. The company
is one of the leading medical product companies in the Northeastern China. HEGLN
employs over 1,000 employees, with more than 200 R&D staff. The company has
successfully commercialized forty-five proprietary products, and has a research
pipeline of over thirty proprietary products. HEGLN is ISO certified and US FDA
compliant.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024